Arenobufagin
(Synonyms: 沙蟾毒精) 目录号 : GC32837
A cardiotonic steroid with anticancer activity
Cas No.:464-74-4
Sample solution is provided at 25 µL, 10mM.
Arenobufagin is a cardiotonic steroid that has been found in the skin secretions of the toad B. gargarizans and has anticancer activity.1,2,3,4 It inhibits Na+/K+-ATPase activity in isolated guinea pig ventricular myocytes with an IC50 value of 290 nM.1 Arenobufagin (20-500 nM) induces cleavage of poly(ADP-ribose) polymerase (PARP), caspase-3, and caspase-9, as well as induces apoptosis in HepG2 hepatocellular carcinoma cells.2 It inhibits proliferation of HepG2, Hep3B, BEL-7402, and MCF-7 cancer cells (IC50s = 101.9, 39.8, 416.3, and 143.7 nM, respectively), as well as multidrug-resistant HepG2/adm and MCF-7/adr cancer cells (IC50s = 730 and 67.5 nM, respectively). Arenobufagin (1 mg/kg once per day, i.v.) reduces tumor growth, the number and size of lung metastases, and tumor levels of the epithelial-to-mesenchymal transition (EMT) markers vimentin and β-catenin in a PC3 mouse xenograft model.3 Arenobufagin (5 and 10 ?M/plug) inhibits VEGF-induced angiogenesis in a Matrigel? plug assay in mice.4
1.dos Santos Cruz, J., and Matsuda, H.Arenobufagin, a compound in toad venom, blocks Na+-K+ pump current in cardiac myocytesEur. J. Pharmacol.239(1-3)223-226(1993) 2.Zhang, D.-M., Liu, J.-S., Deng, L.-J., et al.Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/ mTOR pathwayCarcinogenesis34(6)1331-1342(2013) 3.Chen, L., Mai, W., Chen, M., et al.Arenobufagin inhibits prostate cancer epithelial-mesenchymal transition and metastasis by down-regulating β-cateninPharmacol. Res.123130-142(2017) 4.Li, M.W., S., Liu, Z., Zhang, W., et al.Arenobufagin, a bufadienolide compound from toad venom, inhibits VEGF-mediated angiogenesis through suppression of VEGFR-2 signaling pathwayBiochem. Pharmacol.83(9)1251-1260(2012)
Cas No. | 464-74-4 | SDF | |
别名 | 沙蟾毒精 | ||
Canonical SMILES | C[C@]([C@@H](C(C=C1)=COC1=O)CC2)(C3=O)[C@]2([C@@](CC[C@@]4([H])[C@@]5(CC[C@H](O)C4)C)([H])[C@]5([H])[C@@H]3O)O | ||
分子式 | C24H32O6 | 分子量 | 416.51 |
溶解度 | Ethanol : 10 mg/mL (24.01 mM) | 储存条件 | Store at 2-8°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
![]() |
1 mg | 5 mg | 10 mg |
1 mM | 2.4009 mL | 12.0045 mL | 24.009 mL |
5 mM | 0.4802 mL | 2.4009 mL | 4.8018 mL |
10 mM | 0.2401 mL | 1.2005 mL | 2.4009 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet